Abstract 4887
Background
Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor, comprising less than 1% of head and neck neoplasms. Adjuvant radiotherapy (aRT) is suggested for late-stage disease (stage III or IV); however, recent evidence suggests that it may be associated with improved survival even for early-stage disease. Moreover, the prognostic significance of tumor location on overall (OS) and ACC-specific (ACC-S) survival is unclear. We sought to address these knowledge gaps via analyses of the Surveillance, Epidemiology and End Results (SEER) database.
Methods
Intraoral minor (m) and major (M) ACCs from the SEER database (1973-2015) were selected for analysis. Information on age, sex, race, site, stage, treatment and survival was retrieved. The associations of tumor site and aRT with OS and ACC-S were estimated using hazard ratios (HR) and corresponding 95% confidence intervals (CI) obtained via Cox regression models adjusted for covariates as appropriate. Analyses were done using Stata 15.1 (StataCorp LP, College Station, TX).
Results
There were 635 minor and 1,064 major (parotid: n = 547, submandibular: n = 470, sublingual: n = 47) ACC cases included in the analyses. Late-stage patients (49% of total) were significantly more likely to have received aRT (76% vs. 66%; P < 0.01) compared to those with early-stage disease. Submandibular was the only tumour site that demonstrated statistically significant survival differences compared to the other sites; i.e., worse OS (HR = 1.4; 95% CI = 1.1-1.8) and ACC-S (HR = 1.7; 95% CI = 1.2-2.3) compared to minor ACCs. This difference was only evident for late-stage tumours: stage IV submandibular cases had worse OS (HR = 2.1; 95% CI = 1.5-2.8) and ACC-S (HR = 2.4; 95% CI = 1.7-3.4) compared to stage IV minor ACCs. Overall, aRT was associated with better OS (HR = 0.7; 95% CI = 0.6-0.9) and ACC-S (HR = 0.8; 95% CI = 0.6-1.1). This beneficial effect was more pronounced and statistically confirmed only in stage IV disease.
Conclusions
These results, based on SEER data, suggest that aRT is associated with favorable survival only in late-stage ACC and that, among these late-stage tumors, submandibular gland ACCs have substantially worse prognosis than other sites, irrespective of aRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Academy of Athens PhD Scholarship to Jason Tasoulas; UNC Lineberger Tier 3 Developmental Award funds and the University Cancer Research Fund to A.L. Amelio.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract